ReviewNature reviews. Clinical oncology2011
Implementing prognostic and predictive biomarkers in CRC clinical trials.
Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Clinical lung cancer · 2011Pooled it
- High expression of long non-coding RNA Linc-A associates with poor survival in patients with colorectal cancer.Molecular biology reports · 2020Trial
- Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.Cancer control : journal of the Moffitt Cancer CenterTrial
- Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Induction of ferroptosis in oxaliplatin-resistant colorectal cancer cells by extract fromTranslational cancer research · 2025Article
- Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer.Frontiers in pharmacology · 2025Article
- Exploring prognostic biomarkers in pathological images of colorectal cancer patients via deep learning.The journal of pathology. Clinical research · 2024Article
- Article
- PPP2R1B abolishes colorectal cancer liver metastasis and sensitizes Oxaliplatin by inhibiting MAPK/ERK signaling pathway.Cancer cell international · 2024Article
- Design a Clinical Research Protocol: Influence of Real-World Setting.Healthcare (Basel, Switzerland) · 2023Review
- Circulating lncRNA EGFR-AS1 as a diagnostic biomarker of colorectal cancer and an indicator of tumor burden.Journal of gastrointestinal oncology · 2022Article
- Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.Signal transduction and targeted therapy · 2022Article
- Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC.Frontiers in immunology · 2022Article
- Article
- A methylation-driven gene panel predicts survival in patients with colon cancer.FEBS open bio · 2021Article
- Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.Molecular cancer therapeutics · 2021Article
- HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome.NPJ genomic medicine · 2021Article
- Non-coding RNAS and colorectal cancer liver metastasis.Molecular and cellular biochemistry · 2020Review
- Review
- Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.PLoS medicine · 2020Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, several protein and genomic markers have refined the prognostic information of colorectal cancer (CRC) and helped to predict which patient group may benefit most from systemic treatment or targeted therapies. Of all these markers, KRAS represents the first biomarker integrated into clinical practice for CRC. Microarray-based gene-expression profiling has been used to identify prognostic signatures and to a lesser degree predictive signatures in CRC; however, common challenges with these types of studies are clinical study design, reproducibility, interpretation and reporting of the results. We focus on the clinical application of a range of published prognostic and predictive protein and genomic markers in CRC and discuss the different challenges associated with microarray-based gene-expression profiling. While none of these genomic signatures is currently in routine clinical use in CRC, novel adaptive clinical trial designs that incorporate putative genomic prognostic/predictive markers in prospective randomized trials, will enable a clinical validation of these markers and may facilitate the implementation of these biomarkers into routine medical practice.
Indexed as
Identifiers
21321566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.